Arcus Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
Arcus Biosciences reports increased net losses in 2025, discontinues a Phase 3 trial, but strengthens its financial position with new equity and debt financing.
NYSE
Arcus Biosciences' 10-K filing summarizes the company's focus on developing cancer therapies, key collaborations, and financial results for the year ended December 31, 2024.
NYSE
Arcus Biosciences has established a new severance benefits plan for eligible employees and filed its annual report on Form 10-K, detailing its financial performance and strategic initiatives.